SlideShare a Scribd company logo
Wilson disease 
Presented by A.H. Hosseini MD
COPPER METABOLISM 
• Recommended – 0.9 mg/d 
• Absorbed from duodenum & prox.SI 
• Transported in portal circulation bound protein 
to liver 
• Liver synthesize Cu bound ceruloplasmin & 
excrete copper into bile 
• Stored in liver bound with metallathionein
HISTORY 
• 1912- by Samuel alexander Kinnear Wilson : 
“progressive lenticular degeneration” 
• In 1921, Hall further characterized hepatic 
involvement and introduced the term 
hepatolenticular degeneration. 
• Using positional cloning techniques in 1993, three 
groups independently reported the identification of 
the gene responsible for Wilson’s disease, 
designated ATP7B
EPIDEMIOLOGY 
• autosomal recessive inheritance, thus consanguinity is relatively common in 
affected families 
• a worldwide prevalence of approximately 1 in 30,000 and the heterozygote 
carrier state in approximately 1 in 90 persons 
• marked differences in organ system involvement and biochemical findings, 
suggesting that polygenic or environmental factors may play a role in 
expression of the disease 
• Forty to 60% of patients: hepatic presentation in the second decade of life 
• The remainder of patients come to clinical attention during the third and fourth 
decades with a primarily neurologic (34%) or psychiatric (10%) presentation 
• All patients have liver involvement, although it may be asymptomatic and well 
compensated
GENETICS 
• Wilson’s disease gene is on the long arm of chromosome 13 
• over 250 distinct mutations identified from patients with Wilson’s 
disease 
• Most of these are small deletions or missense mutations, 
• Missense mutations are associated with a predominance of neurologic 
symptoms and a later clinical presentation. 
• Deletions and other mutations causing premature stop codons are 
associated with an earlier clinical presentation predominated by 
symptoms of liver disease 
• Haplotype analysis (microsatellite markers) may be particularly helpful 
in evaluating relatives of a known case
PATHOGENESIS 
• Mutations in ATP7B 
• impaired biliary copper excretion , 
• progressive accumulation of copper in the liver followed by subsequent 
deposition in other organs. 
• defective hepatocyte incorporation of copper into ceruloplasmin 
• failure to clear the high hepatic copper burden 
• intestinal absorption of copper was not increased
• Serum ceruloplasmin levels are low in Wilson’s disease 
because of decreased synthesis of holoceruloplasmin and 
rapid clearance of apoceruloplasmin 
• Heterozygotes for Wilson’s disease may have low 
ceruloplasmin levels yet no pathologic accumulation of 
copper in tissues 
• The normal ceruloplasmin level results from ceruloplasmin 
being an acute phase reactant. In addition, circulating 
apoceruloplasmin may be detected by newer immunologic 
assays for ceruloplasmin
CLINICAL FEATURES OF WILSON’S DISEASE 
• clinical manifestations of Wilson’s disease are rarely apparent before age 5 
years 
• before age 10 years: 83% of patients presented with hepatic 
symptoms and 17% with neuropsychiatric manifestations; 
• between 10 and 18 years: 52% presented with hepatic and 
48% with neuropsychiatric symptoms; 
• after age 18 years: 24% presented with hepatic and 74% 
with neuropsychiatric symptoms 
• all ages: approximately 49% of patients present with hepatic 
and 46% with neuropsychiatric symptoms
AS A RULE… 
A combination of liver dysfunction and other 
organ system involvement, at any age, should 
suggest Wilson’s disease.
KAYSER–FLEISCHERRING RINGS 
• After hepatic saturation, copper accumulating in the ocular cornea 
• a greenish brown ring at the periphery of the cornea on its posterior surface in 
Descemet’s membrane 
• Slit lamp examination 
• Treatment with copper chelators results in gradual resolution of the rings over 
3–5 years 
• The K-F ring does not interfere with visual function 
• The K-F ring is virtually always present at the time when neurologic or 
psychiatric symptoms develop, although there are rare exceptions (5% of 
patients with neurologic symptoms)
• The K-F ring is not pathognomonic for Wilson’s disease ; prolonged 
cholestatic, liver disease, such as chronic hepatitis, chronic intrahepatic and 
neonatal cholestasis, cryptogenic cirrhosis, and primary biliary cirrhosis 
• Absence of KF rings doesn’t exclude diagnosis even in neurological disease 
• grayish brown “sunflower cataract” ; deposits of copper in the 
anterior and posterior lens capsule 
• they rarely interfere with vision and resolve with therapy 
 The other circumstance in which these cataracts may develop is from a copper - 
containing foreign body lodged intraocularly (chalcosis)
spectrum of disease
HEPATIC PRESENTATION 
• Clinical symptoms of liver disease virtually never occur before age 3–5 
years 
• asymptomatic mild elevation of serum amino transferase levels 
 All children and adults who have unexplained chronically elevated serum 
aminotransferase levels require a serum ceruloplasmin, slit-lamp examination, 24-hour 
urine copper excretion, and most likely, a liver biopsy to establish the underlying 
diagnosis 
• acute hepatitis(Clinical signs of jaundice, anorexia, nausea, malaise, pale stools, and 
dark urine mimic infectious hepatitis
• fulminant hepatic failure (Symptoms progress to fatigue, hepatic 
insufficiency, extreme jaundice (because of the accompanying hemolysis), severe 
coagulopathy, ascites, hepatic coma, renal failure, and death if liver transplantation is not 
performed ) 
• In one study of patients in this clinical setting, a ratio of 
o appeared to be diagnostic of Wilson’s disease
POINT!!! 
• A similar, and unfortunate, fulminant presentation has been described 
in patients who had been successfully treated for up to 20 years with 
copper chelators but who discontinued therapy or became 
noncompliant for as little as 8 months’ time 
• Similar presentations have occurred after the discontinuation of zinc 
therapy
• Chronic hepatitis (during adolescence or young adulthood, Malaise, anorexia, 
fatigue, abdominal pain, and nausea may precede the onset of jaundice and hepatic 
dysfunction ) 
 polyarthralgias, edema, gynecomastia, ascites, clubbing, or spider angiomata, when 
present, indicate the chronic nature and likelihood of hepatic fibrosis or cirrhosis 
• cirrhosis (Although cirrhosis and its complications are relatively common 
presenting features of Wilson’s disease in childhood, the disease may remain silent 
and asymptomatic well into adulthood, when patients present with neurologic, 
psychiatric, endocrine, or other symptoms.
AS A RULE….. 
• all children age 3–4 years or older with 
cirrhosis should undergo evaluation for 
Wilson’s disease
• Cholelithiasis: common in adolescents with Wilson’s disease and 
results from ongoing hemolysis in the presence of cirrhosis 
• Abdominal pain in a patient with Wilson’s disease should prompt 
ultrasonographic evaluation for gallstones. 
• Interestingly, the copper content of gallstones removed from Wilson’s 
disease patients was significantly lower than that in pigment stones.
• intra-abdominal malignancies (primarily hepatomas, 
cholangiocarcinomas, and poorly differentiated adenocarcinomas) 
• No case of hepatocellular carcinoma has been 
reported in an affected child or adolescent.
NEUROLOGICAL 
• - Neurologic symptomatology is generally limited to motor 
manifestations of extrapyramidal or cerebellar dysfunction 
• often second-third decade 
• Tremor (resting, intention) 
• Drooling, hypersalivation 
• Dysarthria 
• Coordination defects, clumsiness Dystonia 
Writing difficulties Choreiform movements 
• Ataxic gait 
Headache 
Seizures
BRAIN MRI CORRELATION OF NEUROLOGIC 
FINDINGS 
• pseudoparkinsonian 
• pseudosclerosis 
• dyskinesia
PSYCHIATRIC 
• Organic dementia 
• Neuroses, Anxiety, 
• depression, 
• Obsessive/ compulsive disorder 
• Schizophrenia 
• Bipolar disorder 
• Antisocial behavior 
• Alcoholism
RENAL 
• Nephrolithiasis 
• Proximal renal tubular dysfunction. 
• Distal renal tubular acidosis is reflected by the inability to 
acidify urine to a pH of less than 5.2 in response to an 
ammonium chloride load 
• increased tendency for formation of renal stones 
• end-stage liver disease may develop severe renal 
insufficiency requiring temporary dialysis. 
• Isosthenuria
• severe proteinuria and the nephrotic 
syndrome or a Goodpasture- like syndrome 
are more likely to occur as a consequence of 
penicillamine administration rather than of 
copper toxicity
HEMATOLOGICAL 
• - Coombs neg. hemolytic anemia 
- transient jaundice 
- acute intra vascular hemolysis 
• When associated with the acute fulminant hepatic presentation, 
hemolysis is a poor prognostic factor, contributing to renal failure by 
excess hemoglobinuria 
• circulating hepatic-derived coagulation factor levels may be low, 
platelets may have impaired function, and portal hypertension may 
cause splenomegaly and resultant thrombocytopenia and leukopenia
CARDIAC INVOLVEMENT 
• Electrocardiographic, including left ventricular 
hypertrophy, ST wave depression, and T wave 
inversion. 
• Arrhythmias 
• orthostatic hypotension (although asymptomatic), 
indicating autonomic dysfunction.
SKELETAL MANIFESTATIONS 
• may even be the first clinical symptoms of the disease 
• Bone demineralization is the most common feature possibly caused by the 
hypercalciuria and hyperphosphaturia resulting from renal tubular dysfunction 
• Other radiologic changes include rickets and osteomalacia, 
osteoporosis, spontaneous fractures, bone fragmentation 
near joints 
• Stiffness of larger joints is a complaint of many patients
SKIN MANIFESTATIONS 
• Skin pigmentation on the anterior aspect of the 
lower legs, because of deposition of melanin 
• acanthosis nigricans 
• Blue lunulae of the fingernails
ENDOCRINE ABNORMALITIES 
• Hormonal imbalance secondary to chronic liver disease has 
been thought to lead to amenorrhea in women and 
gynecomastia in boys 
• increased androgen levels and abnormalities in the 
hypothalamic–pituitary–testicular axis in males 
• Additional infrequent associations with Wilson’s disease include 
diabetes mellitus exocrine pancreatic insufficiency & 
hypoparathyroidism
Laboratory Findings
• Patients with Wilson’s disease may present with almost any 
combination of abnormalities in liver blood tests, or even no 
abnormality at all 
• Serum aminotransferase levels are characteristically only mildly to 
moderately elevated, with AST > ALT 
• Serum alkaline phosphatase is usually in the low range 
• Serum phosphate and uric acid may be low because of renal tubular 
losses 
• Changes on radiologic evaluation of the skeleton may include 
osteoporosis, rickets, osteomalacia, localized demineralization, 
osteoarthritis, and other lesions
DIAGNOSIS 
• No single laboratory test result can establish this diagnosis without 
confirmatory clinical and laboratory data, with the possible exception of 
genetic testing under certain circumstances 
• Liver function tests 
• Serum ceruloplasmin 
• Urinary copper excretion 
• Hepatic parenchymal copper concentration 
• Liver biopsy 
• Neuro radiological imaging 
• Genetic studies
SERUM OR PLASMA CERULOPLASMIN 
• Synthesized in liver-acute phase reactant 
• level less than 20 mg/dL suggests the diagnosis of Wilson’s disease 
• LOW levels seen in patients with massive protein loss, kwashiorkor, 
severe copper deficiency, severe hepatic insufficiency, hereditary 
hypoceruloplasminemia, or aceruloplasminemia, or fulminant hepatitis; in 
the normal neonate; in those with Menkes’ syndrome; and in 10% of 
heterozygotes for Wilson’s disease 
• Level < 5 mg/dl: strong evidence of WD 
• If the serum ceruloplasmin concentration is greater than 20 but less than 35 mg/dL, the 
diagnosis of Wilson’s disease is not excluded
• If ceruloplasmin is normal but there is a high index of suspicion, then 
① a 24-hour urine copper excretion (best after penicillamine challenge), 
② slit-lamp examination, and 
③ liver biopsy 
should be performed to confirm or exclude the diagnosis. 
• If a sibling has Wilson’s disease, then haplotype analysis can 
potentially be performed.
the diagnosis of Wilson’s disease must be 
confirmed by 
• an elevated urine 24-hour copper excretion above 100 μg/24 hr (normal, 
<40 μg/ 24 hr), 
• an elevated urine copper during a penicillamine challenge 
• the presence of a K-F ring (and the absence of other cholestatic liver 
disorders), 
• elevated hepatic copper content (>250 μg/g dry weight) with consistent 
liver histology
URINARY COPPER 
• 24 hr urinary Cu excretion 
• Dx & monitoring 
• Basal 24 hr urine Cu > 100 μg in symptomatic WD 
• But > 40 μg may indicate WD , req. further test 
• Pencillamine challenge test 
500 mg D-pencillamine orally at beginning and 
repeat after 12 hr during 24hr urine collection 
> 1600 μg Cu/24 hr urine - positive
24 HOUR URINE 
• Urine must be collected in copper-free containers to avoid 
contamination 
• Additionally, determining if the collection was a full 24-hour 
collection should be confirmed by measuring total urinary 
creatinine excretion (normal, 10–20 mg/kg/ 24 hr). 
• False-positive results of a 24-hour urine copper excretion 
(i.e., >100 μg/24 hr) may be seen if the patient is receiving 
any type of copper chelation therapy, if the collection is 
contaminated by exogenous copper, or if the patient has 
chronic active hepatitis, cholestatic cirrhosis, or nephrotic 
syndrome
SERUM FREE COPPER 
• Increased level of serum “free” copper 
• Serum free Cu is non-ceruloplasmin bound Cu 
• Total S.Cu (mcg/dl)- 3x serum ceruloplasmin 
Cu (μg/dl) 
• Normal level<15 mcg/dl 
• > 25 mcg/dl in untreated WD 
• < 5mcg/dl indicates over-treated
HEPATIC PARENCHYMAL COPPER 
CONCENTRATION 
• Normal - <40-50μg/g dry wt. liver 
• Critical value- > 250 μg/g dry wt. 
• Further evaluation needed if 70- 250μg/g ,if 
active liver d/s or symptoms of WD
LIVER BIOPSY 
• Mild steatosis- earliest 
• Auto immune hepatitis histologic findings 
• Cirrhotic changes-macronodular 
• marked hepatocellular degeneration & parenchymal 
collapse 
• Cu staining is variable- poor predictive value
NEURO-IMAGING 
 Brain CT abnormalities: 
• 73% with ventricular dilation, 63% cortical atrophy, 55% brainstem 
atrophy, 45% hypodense areas in basal ganglia, and 10% posterior 
fossa atrophy. 
• MR imaging- evaluate neurologic WD & prior to 
treatment 
• MRI- T2 hyperintensity in basal ganglia,thalami
GENETIC STUDIES 
• Molecular genetic testing has been available in recent years and is most helpful if the 
diagnosis remains in doubt 
• DNA mutation analysis can be performed for a defined ATP7B mutation, 
• common mutations in the appropriate ethnic population 
• haplotype (microsatellite) marker analysis if a first-degree relative has Wilson’s 
disease. 
• Prenatal diagnosis ???
 Tests that appear to be of no value in establishing the diagnosis of 
Wilson’s disease 
• computed tomography (CT) scanning & 
• MRI of the liver, 
 because liver copper content cannot currently be detected or 
quantitated by these modalities
AN ASYMPTOMATIC PATIENT IN WHOM A K-F RING IS FOUND 
ON ROUTINE OPHTHALMOLOGIC EXAMINATION 
① a serum ceruloplasmin level should be performed. 
② If it is low or there is high suspicion and it is normal, 
③ a 24-hour urine copper excretion should be performed and 
consideration given to a liver biopsy. 
④ Elevated urine copper excretion, a low ceruloplasmin, and a K-F ring 
establish the diagnosis. 
⑤ However, if the liver or spleen is enlarged or liver blood tests are 
abnormal, a liver biopsy should be performed.
ASYMPTOMATIC SIBLINGS OF WILSON’S DISEASE PATIENTS 
① screened for the disease after age 3 or 4 years unless hepatomegaly or 
abnormal aminotransferase levels are found earlier. 
② A thorough history and physical examination, slit-lamp examination, 
and laboratory analysis should be performed 
③ If all tests are normal, it is very unlikely that the relative has Wilson’s 
disease 
④ However, if any of those tests are abnormal, a liver biopsy should be 
performed for histology, electron microscopy, and quantitative copper 
analysis.
⑤ An alternative, less invasive approach is to evaluate the known 
patient, the sibling, and the parents for DNA haplotype (microsatellite 
markers) to determine if the sibling in question has inherited the 
Wilson’s disease gene. 
⑥ Haplotype analysis is informative in over 90–95% of cases 
⑦ Another approach is to genotype the affected relative and if ATP7B 
mutations are identified, to test the sibling in question for these 
mutations. 
⑧ Finding two mutations or informative microsatellite markers will 
establish the diagnosis of Wilson’s disease and preclude the need for 
liver biopsy unless there are signs or symp- toms of chronic liver 
disease
treatment
• Anti –copper drugs- 
-D-Pencillamine 
- Zinc 
- Trientene 
- Tetrathiomolybdate(TM) 
• Diet 
• Drinking water 
• Concomitant hepatic,neurological management 
• Liver transplantation
D-PENICILLAMINE 
• a sulfhydryl- containing metabolite of penicillin 
• The actual mechanism on how this drug works is not 
known 
• “decoppering effect,” 
• “detoxification effect” 
• It is recommended to begin the penicillamine therapy 
with one fourth to half of the desired dose and increase 
the dose slowly over 1–2 weeks.
• The dosage for older children and adults is 1 g of penicillamine 
orally per day in four divided doses given ideally at least 30 
minutes before or 2 or more hours after meals. 
• If an overtly ill patient fails to show clinical improvement, the 
dosage can be increased to 1.5–2.0 g/d. 
• In young children, a dosage of 20 mg/kg/d rounded to the nearest 
multiple of 250 mg is given ideally in three divided doses 
• After stabilization, the dose may be divided into two or three 
daily doses not to be given with meals 
• D-penicillamine may have an antipyridoxine effect, thus all 
treated patients should also receive 25–50 mg of pyridoxine daily
• During the first month of penicillamine therapy, the patient 
should be monitored weekly for fever or rash. 
• A complete blood count and platelet count, urinalysis, and 
renal and liver blood tests should be obtained every 1–2 
weeks 
• If the patient responds appropriately with resolution of symptoms and 
normalization of liver blood tests, monitoring is performed every 1–3 months 
for the first year and every 6–12 months thereafter. 
• An annual 24-hour urinary copper excretion is helpful in 
mon- itoring chronic penicillamine therapy
• In 10–50% of patients, neurologic symptoms worsened shortly after 
penicillamine therapy was started 
• Continued or altered penicillamine therapy generally resulted in 
reversal of this worsening although irreversible neurologic 
abnormalities have been reported 
• Thus, it is recommended that the penicillamine dosage be reduced to 
250 mg/d if neurologic symptoms worsen and gradually increased every 
4–7 days by 250 mg/d until urinary copper excretion exceeds 2000 μg/d
TRIETHYLENE TETRAMINE DIHYDROCHLORIDE 
(TRIENTINE) 
• It does not contain sulfhydryl groups; rather it chelates copper by forming a 
stable complex with copper through its four nitrogen atoms in a planar ring. 
• better safety profile. 
• The initial dosage for adolescents and adults is 750–1500 mg daily in two to 
three divided doses before meals. 
• Maintenance therapy is typically 750 or 1000 mg/d. 
• In children, the dose generally used is 20 mg/kg/d rounded off to the nearest 
250 mg. 
• The toxicity includes bone marrow suppression (a sideroblastic anemia), 
nephrotoxicity, and skin and mucosal lesions . 
• Female patients may become iron deficient and require iron supplementation
AMMONIUM TETRATHIOMOLYBDATE 
• an alternative approach to the treatment of Wilson’s disease is based 
on whether the patient presents with neurologic or hepatic symptoms 
• Because up to 50% of patients in an earlier series who had neurologic 
disease showed worsening of their symptoms with penicillamine 
therapy, ammonium tetrathiomolybdate, for initial therapy in 
neurologically affected patients 
• it is absorbed and complexes with copper and albumin in blood, 
preventing cellular uptake and resulting in decreased intracellular 
copper stores 
• After 8 weeks, the drug was stopped and patients were maintained on 
oral zinc acetate, 50 mg three times a day
- inhibit CU absorption 
- bind with copper (chelator) 
- used in neurological WD 
- S/E- anemia,neutropenia, 
hepatotoxicity 
- 120 mg/d ie. 20mg x 3 with meal 
60mg bed time 
- 8 weeks therapy 
- weekly neurological examination
ZINC THERAPY 
• Zinc has been proposed as maintenance or adjunctive therapy for Wilson’s disease. 
• Zinc inhibits intestinal absorption of copper 
• The dosage of zinc acetate, given between meals, that currently is advocated is 50 
mg of elemental zinc three times daily or zinc sulfate, 150– 220 mg three times daily 
• Common side effects include headache and gastrointestinal upset, which are 
perhaps less common with zinc acetate. 
• Because of its slower onset of action, zinc therapy is generally not used as initial 
therapy for symptomatic patients. 
• Zinc therapy may play a role in presymptomatic patients or siblings 
• It should also be stressed that patients have deteriorated and developed fulmi- nant 
liver failure after the discontinuation of zinc therapy.
ANTIOXIDANT THERAPY 
• Vitamin E, 400–1200 IU/d, may be given orally in divided doses 
with meals safely. 
• Because high-dose vitamin E may interfere with vitamin K– 
dependent clotting factor synthesis, the prothrombin time should 
be monitored and vitamin K supplementation used if necessary.
LIVER TRANSPLANTATION 
• acute fulminant hepatic failure, 
• those with fulminant hepatic failure after inadvisably discontinuing copper 
chelation therapy 
• decompensated cirrhosis unresponsive to medical therapy 
• To better determine the criteria for referral for liver transplantation, Nazer et 
al. developed a prognostic index based on grading from 1–4 points the 
serum bilirubin concentration, serum AST, and prolongation of prothrombin 
time
NAZER PROGNOSTIC INDEX 
Lab 
measureme 
nt 
normal 
value 
Score 
0 
Score 
1 
Score 
2 
Score 
3 
Score 
4 
Serum 
bilirubin 
0.2-1.2 <5.8 5.8-8.8 8.9-11.7 11.8-17.5 >17.5 
SGOT 10-35 <100 100-150 151-200 201-300 >300 
PT 
prolongation 
diff. 
12-14s <4s 4-8s 9-12 13-20 >20
NAZER INDEX 
• Mild hepatic failure- score <6 survived with medical therapy 
• Moderate hepatic failure- 7-9 
• Severe hepatic Failure - >9 fatal courses or required transplantation 
• The authors developed a new index based on serum bilirubin, INR, AST, 
albumin, and WBC at presentation. 
• A score greater than 11 of a possible 20 was predictive for death, with a 93% 
sensitivity, 98% specificity, and 88% positive predictive value
SPECIAL CIRCUMSTANCES 
 PREGNANCY 
• During pregnancy, it is advisable to continue penicillamine therapy at a dosage 
of 750–1000 mg/d 
• Several patients who have discontinued therapy for longer periods during 
pregnancy have had episodes of acute hemolysis or worsening of liver disease 
including fulminant hepatic failure. 
• All children fathered by patients with Wilson’s disease have been normal 
• Although infants may be at a small risk for a connective tissue or skin 
abnormality during penicillamine therapy, the risk to mother and infant of 
discontinuing copper chelation therapy appears to be greater. 
• If cesarean section is anticipated, some authorities recommend reducing the 
dose of penicillamine to 250 mg/d 6 weeks before delivery to reduce the risk for 
impaired wound healing
 SURGERY 
• Penicillamine has inhibitory effects on collagen cross- linking 
• Therefore, to prevent interference with wound healing, it is 
recommended that when patients with Wilson’s disease undergo 
surgery, the dose of penicillamine be reduced, but not stopped, for 10– 
14 days postoperatively
DIET 
• Avoid liver ,shell fishes,nuts,chocolate,mushroom 
• After 6-12 months Rx, one meal + shell fish/ wk 
• If enteral feeding,Cu <1.5 mg/d 
• Drinking water - < 0.1 ppm Cu
ANTI COPPPER DRUGS 
Drugs Mode of action Neurological 
deterioration 
S/E Dosage monitoring 
D-pencillamine Chelator 
induces 
cupuria 
1 
20-40 % in 
initial phase 
BM 
suppression,ne 
phrotic 
syndrome, 
Hepatotoxicity,f 
ever, 
250- 
500mg/d,incre 
mental 
250mg4-7d 
Max.1-1.5g/d ( 
2-4 doses) 
Maint-750mg- 
1g 
Pyridoxine- 
25mg/d 
24hr.U Cu-200- 
500μg 
Free Cu- 
10-15μg/dl 
1,3,6,12,18, 
24 months 
Then 
annually
DRUGS MODE OF ACTION SIDE EFEECTS DOSAGE MONITOR 
Trientine Chelator induces 
cupuria 
Gastritis,aplastic 
anemia rare, 
Sideroblastic 
anemia 
750-1500mg/d 
(2-3 doses) 
20mg/kg/d(child 
Maint- 
750-1000mg 
24hr U.Cu & 
Non-ceruloplas 
Bound copper 
1,3,6,12,18,24 
months-annually 
Zinc 
Metallothione 
inducer, 
Inhibits Cu 
absoption 
Gastritis,pancreatitis 
,Zn accumulation 
150mg/d in 3 
divided doses 
75mg/d 
(child, <50 kg) 
24hr .U.Cu- 
50-125μg/d 
& 
24h.U.Zn 
> 2mg/d 
3,6 months,6 month 
2yr,then yearly
SUMMARY 
• WD- is an medical enigma with wide spectrum 
• Proper clinical examinations 
• Integrated diagnostic approach 
• Treatment for various clinical profiles 
• Zinc as a new paradigm shift in Rx 
• Hepatic transplantation 
• Monitoring., and prognosis 
• Lifelong Rx and normal expectancy 
• Fatal if not treated.
Wilson Disease

More Related Content

What's hot

pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)student
 
Wilson's Disease
Wilson's DiseaseWilson's Disease
Wilson's Disease
Pratap Tiwari
 
Wilson’s disease academic
Wilson’s disease academicWilson’s disease academic
Wilson’s disease academic
Kiran Bikkad
 
Renal tubular acidosis
Renal tubular acidosisRenal tubular acidosis
Renal tubular acidosis
Azad Haleem
 
Polycystic kidney disease
Polycystic kidney disease Polycystic kidney disease
Polycystic kidney disease
Aayusha Bhandari
 
Hemochromatosis presentation
Hemochromatosis presentationHemochromatosis presentation
Alport
AlportAlport
Case scenarios in wilson disease by Dr Aabha Nagral
Case scenarios in wilson disease by Dr Aabha NagralCase scenarios in wilson disease by Dr Aabha Nagral
Case scenarios in wilson disease by Dr Aabha NagralSanjeev Kumar
 
Presentation1 pseudotumor
Presentation1 pseudotumorPresentation1 pseudotumor
Presentation1 pseudotumor
Drgeeta Choudhary
 
Congenital adrenal hyperplasia
Congenital adrenal hyperplasia Congenital adrenal hyperplasia
Congenital adrenal hyperplasia
Manoj Prabhakar
 
Renal tubular acidosis
Renal tubular acidosisRenal tubular acidosis
Renal tubular acidosis
irock0722
 
wilson's disease
 wilson's disease wilson's disease
wilson's disease
Abdul Waris
 
Non Alcoholic Steatohepatitis
Non Alcoholic SteatohepatitisNon Alcoholic Steatohepatitis
Non Alcoholic Steatohepatitis
Elmuhtady Said FRCP FEBGH
 
Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
Wisit Cheungpasitporn
 
Alports Syndrome Pp
Alports Syndrome PpAlports Syndrome Pp
Alports Syndrome Pp
Dr. Abrar Ali Katpar
 
Neonatal Cholestasis
Neonatal CholestasisNeonatal Cholestasis
Neonatal Cholestasis
Dr. Maimuna Sayeed
 
Chronic Kidney Disease in Pediatrics
Chronic Kidney Disease in PediatricsChronic Kidney Disease in Pediatrics
Chronic Kidney Disease in Pediatrics
Drhunny88
 
Updated management of Wilson's disease
Updated management of Wilson's diseaseUpdated management of Wilson's disease
Updated management of Wilson's disease
BSMMU
 

What's hot (20)

pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)
 
Wilson's Disease
Wilson's DiseaseWilson's Disease
Wilson's Disease
 
Wilson’s disease academic
Wilson’s disease academicWilson’s disease academic
Wilson’s disease academic
 
Renal tubular acidosis
Renal tubular acidosisRenal tubular acidosis
Renal tubular acidosis
 
Polycystic kidney disease
Polycystic kidney disease Polycystic kidney disease
Polycystic kidney disease
 
Hemochromatosis presentation
Hemochromatosis presentationHemochromatosis presentation
Hemochromatosis presentation
 
Alport
AlportAlport
Alport
 
Case scenarios in wilson disease by Dr Aabha Nagral
Case scenarios in wilson disease by Dr Aabha NagralCase scenarios in wilson disease by Dr Aabha Nagral
Case scenarios in wilson disease by Dr Aabha Nagral
 
Presentation1 pseudotumor
Presentation1 pseudotumorPresentation1 pseudotumor
Presentation1 pseudotumor
 
Congenital adrenal hyperplasia
Congenital adrenal hyperplasia Congenital adrenal hyperplasia
Congenital adrenal hyperplasia
 
Renal tubular acidosis
Renal tubular acidosisRenal tubular acidosis
Renal tubular acidosis
 
Alport syndrome
Alport syndromeAlport syndrome
Alport syndrome
 
wilson's disease
 wilson's disease wilson's disease
wilson's disease
 
Non Alcoholic Steatohepatitis
Non Alcoholic SteatohepatitisNon Alcoholic Steatohepatitis
Non Alcoholic Steatohepatitis
 
Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
 
Alports Syndrome Pp
Alports Syndrome PpAlports Syndrome Pp
Alports Syndrome Pp
 
Neonatal Cholestasis
Neonatal CholestasisNeonatal Cholestasis
Neonatal Cholestasis
 
Pseudohypoparathyroidism
PseudohypoparathyroidismPseudohypoparathyroidism
Pseudohypoparathyroidism
 
Chronic Kidney Disease in Pediatrics
Chronic Kidney Disease in PediatricsChronic Kidney Disease in Pediatrics
Chronic Kidney Disease in Pediatrics
 
Updated management of Wilson's disease
Updated management of Wilson's diseaseUpdated management of Wilson's disease
Updated management of Wilson's disease
 

Similar to Wilson Disease

Wilson's disease (wilson)
Wilson's disease (wilson)Wilson's disease (wilson)
Wilson's disease (wilson)
mahadev deuja
 
wilsons disease-18121814300767786654.pdf
wilsons disease-18121814300767786654.pdfwilsons disease-18121814300767786654.pdf
wilsons disease-18121814300767786654.pdf
azizahmed968552
 
Wilsons disease
Wilsons diseaseWilsons disease
Wilsons disease
DivyaBhargavi7
 
Wilson`s disease
Wilson`s diseaseWilson`s disease
Wilson`s disease
Rafiqul Islam
 
AKI.pptx
AKI.pptxAKI.pptx
AKI.pptx
musayansa
 
Anozie chukwuebuka chibueze, Hepatitis in adults.
Anozie chukwuebuka chibueze, Hepatitis in adults.Anozie chukwuebuka chibueze, Hepatitis in adults.
Anozie chukwuebuka chibueze, Hepatitis in adults.
anozie12345
 
Cirrhosis and Its Complications
Cirrhosis and Its ComplicationsCirrhosis and Its Complications
Cirrhosis and Its Complications
ozererik
 
Hematuria
HematuriaHematuria
Hematuria
abdur razzak
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
Dr. Akash Bharti
 
Liver failure
Liver failureLiver failure
Liver failure
Karan Gagneja
 
Liver transplant
Liver transplantLiver transplant
Liver transplant
Dhileeban Maharajan
 
Chronic hepatitis ppt
Chronic hepatitis pptChronic hepatitis ppt
Chronic hepatitis pptManoj Ghoda
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
Kamalsayim
 
Organ involvment in cstinosis [autosaved] [autosaved]2 (1)
Organ involvment in cstinosis [autosaved] [autosaved]2 (1)Organ involvment in cstinosis [autosaved] [autosaved]2 (1)
Organ involvment in cstinosis [autosaved] [autosaved]2 (1)
Pediatric Nephrology
 
medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)student
 
Renal pathology iii
Renal pathology iiiRenal pathology iii
Renal pathology iii
med_students0
 
Acute liver failure
Acute liver failureAcute liver failure
Acute liver failure
mauryaramgopal
 
Chronic liver disease in children22.pptx
Chronic liver disease in children22.pptxChronic liver disease in children22.pptx
Chronic liver disease in children22.pptx
AmmaraHameed6
 
medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)student
 
Approac h to cholestatic jaundice
Approac h to cholestatic jaundiceApproac h to cholestatic jaundice
Approac h to cholestatic jaundice
Arun Karmakar
 

Similar to Wilson Disease (20)

Wilson's disease (wilson)
Wilson's disease (wilson)Wilson's disease (wilson)
Wilson's disease (wilson)
 
wilsons disease-18121814300767786654.pdf
wilsons disease-18121814300767786654.pdfwilsons disease-18121814300767786654.pdf
wilsons disease-18121814300767786654.pdf
 
Wilsons disease
Wilsons diseaseWilsons disease
Wilsons disease
 
Wilson`s disease
Wilson`s diseaseWilson`s disease
Wilson`s disease
 
AKI.pptx
AKI.pptxAKI.pptx
AKI.pptx
 
Anozie chukwuebuka chibueze, Hepatitis in adults.
Anozie chukwuebuka chibueze, Hepatitis in adults.Anozie chukwuebuka chibueze, Hepatitis in adults.
Anozie chukwuebuka chibueze, Hepatitis in adults.
 
Cirrhosis and Its Complications
Cirrhosis and Its ComplicationsCirrhosis and Its Complications
Cirrhosis and Its Complications
 
Hematuria
HematuriaHematuria
Hematuria
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
 
Liver failure
Liver failureLiver failure
Liver failure
 
Liver transplant
Liver transplantLiver transplant
Liver transplant
 
Chronic hepatitis ppt
Chronic hepatitis pptChronic hepatitis ppt
Chronic hepatitis ppt
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
 
Organ involvment in cstinosis [autosaved] [autosaved]2 (1)
Organ involvment in cstinosis [autosaved] [autosaved]2 (1)Organ involvment in cstinosis [autosaved] [autosaved]2 (1)
Organ involvment in cstinosis [autosaved] [autosaved]2 (1)
 
medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)
 
Renal pathology iii
Renal pathology iiiRenal pathology iii
Renal pathology iii
 
Acute liver failure
Acute liver failureAcute liver failure
Acute liver failure
 
Chronic liver disease in children22.pptx
Chronic liver disease in children22.pptxChronic liver disease in children22.pptx
Chronic liver disease in children22.pptx
 
medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)
 
Approac h to cholestatic jaundice
Approac h to cholestatic jaundiceApproac h to cholestatic jaundice
Approac h to cholestatic jaundice
 

Recently uploaded

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 

Recently uploaded (20)

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 

Wilson Disease

  • 1.
  • 2. Wilson disease Presented by A.H. Hosseini MD
  • 3.
  • 4. COPPER METABOLISM • Recommended – 0.9 mg/d • Absorbed from duodenum & prox.SI • Transported in portal circulation bound protein to liver • Liver synthesize Cu bound ceruloplasmin & excrete copper into bile • Stored in liver bound with metallathionein
  • 5. HISTORY • 1912- by Samuel alexander Kinnear Wilson : “progressive lenticular degeneration” • In 1921, Hall further characterized hepatic involvement and introduced the term hepatolenticular degeneration. • Using positional cloning techniques in 1993, three groups independently reported the identification of the gene responsible for Wilson’s disease, designated ATP7B
  • 6. EPIDEMIOLOGY • autosomal recessive inheritance, thus consanguinity is relatively common in affected families • a worldwide prevalence of approximately 1 in 30,000 and the heterozygote carrier state in approximately 1 in 90 persons • marked differences in organ system involvement and biochemical findings, suggesting that polygenic or environmental factors may play a role in expression of the disease • Forty to 60% of patients: hepatic presentation in the second decade of life • The remainder of patients come to clinical attention during the third and fourth decades with a primarily neurologic (34%) or psychiatric (10%) presentation • All patients have liver involvement, although it may be asymptomatic and well compensated
  • 7. GENETICS • Wilson’s disease gene is on the long arm of chromosome 13 • over 250 distinct mutations identified from patients with Wilson’s disease • Most of these are small deletions or missense mutations, • Missense mutations are associated with a predominance of neurologic symptoms and a later clinical presentation. • Deletions and other mutations causing premature stop codons are associated with an earlier clinical presentation predominated by symptoms of liver disease • Haplotype analysis (microsatellite markers) may be particularly helpful in evaluating relatives of a known case
  • 8. PATHOGENESIS • Mutations in ATP7B • impaired biliary copper excretion , • progressive accumulation of copper in the liver followed by subsequent deposition in other organs. • defective hepatocyte incorporation of copper into ceruloplasmin • failure to clear the high hepatic copper burden • intestinal absorption of copper was not increased
  • 9. • Serum ceruloplasmin levels are low in Wilson’s disease because of decreased synthesis of holoceruloplasmin and rapid clearance of apoceruloplasmin • Heterozygotes for Wilson’s disease may have low ceruloplasmin levels yet no pathologic accumulation of copper in tissues • The normal ceruloplasmin level results from ceruloplasmin being an acute phase reactant. In addition, circulating apoceruloplasmin may be detected by newer immunologic assays for ceruloplasmin
  • 10. CLINICAL FEATURES OF WILSON’S DISEASE • clinical manifestations of Wilson’s disease are rarely apparent before age 5 years • before age 10 years: 83% of patients presented with hepatic symptoms and 17% with neuropsychiatric manifestations; • between 10 and 18 years: 52% presented with hepatic and 48% with neuropsychiatric symptoms; • after age 18 years: 24% presented with hepatic and 74% with neuropsychiatric symptoms • all ages: approximately 49% of patients present with hepatic and 46% with neuropsychiatric symptoms
  • 11. AS A RULE… A combination of liver dysfunction and other organ system involvement, at any age, should suggest Wilson’s disease.
  • 12. KAYSER–FLEISCHERRING RINGS • After hepatic saturation, copper accumulating in the ocular cornea • a greenish brown ring at the periphery of the cornea on its posterior surface in Descemet’s membrane • Slit lamp examination • Treatment with copper chelators results in gradual resolution of the rings over 3–5 years • The K-F ring does not interfere with visual function • The K-F ring is virtually always present at the time when neurologic or psychiatric symptoms develop, although there are rare exceptions (5% of patients with neurologic symptoms)
  • 13. • The K-F ring is not pathognomonic for Wilson’s disease ; prolonged cholestatic, liver disease, such as chronic hepatitis, chronic intrahepatic and neonatal cholestasis, cryptogenic cirrhosis, and primary biliary cirrhosis • Absence of KF rings doesn’t exclude diagnosis even in neurological disease • grayish brown “sunflower cataract” ; deposits of copper in the anterior and posterior lens capsule • they rarely interfere with vision and resolve with therapy  The other circumstance in which these cataracts may develop is from a copper - containing foreign body lodged intraocularly (chalcosis)
  • 14.
  • 16. HEPATIC PRESENTATION • Clinical symptoms of liver disease virtually never occur before age 3–5 years • asymptomatic mild elevation of serum amino transferase levels  All children and adults who have unexplained chronically elevated serum aminotransferase levels require a serum ceruloplasmin, slit-lamp examination, 24-hour urine copper excretion, and most likely, a liver biopsy to establish the underlying diagnosis • acute hepatitis(Clinical signs of jaundice, anorexia, nausea, malaise, pale stools, and dark urine mimic infectious hepatitis
  • 17. • fulminant hepatic failure (Symptoms progress to fatigue, hepatic insufficiency, extreme jaundice (because of the accompanying hemolysis), severe coagulopathy, ascites, hepatic coma, renal failure, and death if liver transplantation is not performed ) • In one study of patients in this clinical setting, a ratio of o appeared to be diagnostic of Wilson’s disease
  • 18. POINT!!! • A similar, and unfortunate, fulminant presentation has been described in patients who had been successfully treated for up to 20 years with copper chelators but who discontinued therapy or became noncompliant for as little as 8 months’ time • Similar presentations have occurred after the discontinuation of zinc therapy
  • 19. • Chronic hepatitis (during adolescence or young adulthood, Malaise, anorexia, fatigue, abdominal pain, and nausea may precede the onset of jaundice and hepatic dysfunction )  polyarthralgias, edema, gynecomastia, ascites, clubbing, or spider angiomata, when present, indicate the chronic nature and likelihood of hepatic fibrosis or cirrhosis • cirrhosis (Although cirrhosis and its complications are relatively common presenting features of Wilson’s disease in childhood, the disease may remain silent and asymptomatic well into adulthood, when patients present with neurologic, psychiatric, endocrine, or other symptoms.
  • 20. AS A RULE….. • all children age 3–4 years or older with cirrhosis should undergo evaluation for Wilson’s disease
  • 21. • Cholelithiasis: common in adolescents with Wilson’s disease and results from ongoing hemolysis in the presence of cirrhosis • Abdominal pain in a patient with Wilson’s disease should prompt ultrasonographic evaluation for gallstones. • Interestingly, the copper content of gallstones removed from Wilson’s disease patients was significantly lower than that in pigment stones.
  • 22. • intra-abdominal malignancies (primarily hepatomas, cholangiocarcinomas, and poorly differentiated adenocarcinomas) • No case of hepatocellular carcinoma has been reported in an affected child or adolescent.
  • 23. NEUROLOGICAL • - Neurologic symptomatology is generally limited to motor manifestations of extrapyramidal or cerebellar dysfunction • often second-third decade • Tremor (resting, intention) • Drooling, hypersalivation • Dysarthria • Coordination defects, clumsiness Dystonia Writing difficulties Choreiform movements • Ataxic gait Headache Seizures
  • 24. BRAIN MRI CORRELATION OF NEUROLOGIC FINDINGS • pseudoparkinsonian • pseudosclerosis • dyskinesia
  • 25.
  • 26. PSYCHIATRIC • Organic dementia • Neuroses, Anxiety, • depression, • Obsessive/ compulsive disorder • Schizophrenia • Bipolar disorder • Antisocial behavior • Alcoholism
  • 27. RENAL • Nephrolithiasis • Proximal renal tubular dysfunction. • Distal renal tubular acidosis is reflected by the inability to acidify urine to a pH of less than 5.2 in response to an ammonium chloride load • increased tendency for formation of renal stones • end-stage liver disease may develop severe renal insufficiency requiring temporary dialysis. • Isosthenuria
  • 28. • severe proteinuria and the nephrotic syndrome or a Goodpasture- like syndrome are more likely to occur as a consequence of penicillamine administration rather than of copper toxicity
  • 29. HEMATOLOGICAL • - Coombs neg. hemolytic anemia - transient jaundice - acute intra vascular hemolysis • When associated with the acute fulminant hepatic presentation, hemolysis is a poor prognostic factor, contributing to renal failure by excess hemoglobinuria • circulating hepatic-derived coagulation factor levels may be low, platelets may have impaired function, and portal hypertension may cause splenomegaly and resultant thrombocytopenia and leukopenia
  • 30. CARDIAC INVOLVEMENT • Electrocardiographic, including left ventricular hypertrophy, ST wave depression, and T wave inversion. • Arrhythmias • orthostatic hypotension (although asymptomatic), indicating autonomic dysfunction.
  • 31. SKELETAL MANIFESTATIONS • may even be the first clinical symptoms of the disease • Bone demineralization is the most common feature possibly caused by the hypercalciuria and hyperphosphaturia resulting from renal tubular dysfunction • Other radiologic changes include rickets and osteomalacia, osteoporosis, spontaneous fractures, bone fragmentation near joints • Stiffness of larger joints is a complaint of many patients
  • 32. SKIN MANIFESTATIONS • Skin pigmentation on the anterior aspect of the lower legs, because of deposition of melanin • acanthosis nigricans • Blue lunulae of the fingernails
  • 33. ENDOCRINE ABNORMALITIES • Hormonal imbalance secondary to chronic liver disease has been thought to lead to amenorrhea in women and gynecomastia in boys • increased androgen levels and abnormalities in the hypothalamic–pituitary–testicular axis in males • Additional infrequent associations with Wilson’s disease include diabetes mellitus exocrine pancreatic insufficiency & hypoparathyroidism
  • 35. • Patients with Wilson’s disease may present with almost any combination of abnormalities in liver blood tests, or even no abnormality at all • Serum aminotransferase levels are characteristically only mildly to moderately elevated, with AST > ALT • Serum alkaline phosphatase is usually in the low range • Serum phosphate and uric acid may be low because of renal tubular losses • Changes on radiologic evaluation of the skeleton may include osteoporosis, rickets, osteomalacia, localized demineralization, osteoarthritis, and other lesions
  • 36. DIAGNOSIS • No single laboratory test result can establish this diagnosis without confirmatory clinical and laboratory data, with the possible exception of genetic testing under certain circumstances • Liver function tests • Serum ceruloplasmin • Urinary copper excretion • Hepatic parenchymal copper concentration • Liver biopsy • Neuro radiological imaging • Genetic studies
  • 37. SERUM OR PLASMA CERULOPLASMIN • Synthesized in liver-acute phase reactant • level less than 20 mg/dL suggests the diagnosis of Wilson’s disease • LOW levels seen in patients with massive protein loss, kwashiorkor, severe copper deficiency, severe hepatic insufficiency, hereditary hypoceruloplasminemia, or aceruloplasminemia, or fulminant hepatitis; in the normal neonate; in those with Menkes’ syndrome; and in 10% of heterozygotes for Wilson’s disease • Level < 5 mg/dl: strong evidence of WD • If the serum ceruloplasmin concentration is greater than 20 but less than 35 mg/dL, the diagnosis of Wilson’s disease is not excluded
  • 38. • If ceruloplasmin is normal but there is a high index of suspicion, then ① a 24-hour urine copper excretion (best after penicillamine challenge), ② slit-lamp examination, and ③ liver biopsy should be performed to confirm or exclude the diagnosis. • If a sibling has Wilson’s disease, then haplotype analysis can potentially be performed.
  • 39. the diagnosis of Wilson’s disease must be confirmed by • an elevated urine 24-hour copper excretion above 100 μg/24 hr (normal, <40 μg/ 24 hr), • an elevated urine copper during a penicillamine challenge • the presence of a K-F ring (and the absence of other cholestatic liver disorders), • elevated hepatic copper content (>250 μg/g dry weight) with consistent liver histology
  • 40. URINARY COPPER • 24 hr urinary Cu excretion • Dx & monitoring • Basal 24 hr urine Cu > 100 μg in symptomatic WD • But > 40 μg may indicate WD , req. further test • Pencillamine challenge test 500 mg D-pencillamine orally at beginning and repeat after 12 hr during 24hr urine collection > 1600 μg Cu/24 hr urine - positive
  • 41. 24 HOUR URINE • Urine must be collected in copper-free containers to avoid contamination • Additionally, determining if the collection was a full 24-hour collection should be confirmed by measuring total urinary creatinine excretion (normal, 10–20 mg/kg/ 24 hr). • False-positive results of a 24-hour urine copper excretion (i.e., >100 μg/24 hr) may be seen if the patient is receiving any type of copper chelation therapy, if the collection is contaminated by exogenous copper, or if the patient has chronic active hepatitis, cholestatic cirrhosis, or nephrotic syndrome
  • 42. SERUM FREE COPPER • Increased level of serum “free” copper • Serum free Cu is non-ceruloplasmin bound Cu • Total S.Cu (mcg/dl)- 3x serum ceruloplasmin Cu (μg/dl) • Normal level<15 mcg/dl • > 25 mcg/dl in untreated WD • < 5mcg/dl indicates over-treated
  • 43. HEPATIC PARENCHYMAL COPPER CONCENTRATION • Normal - <40-50μg/g dry wt. liver • Critical value- > 250 μg/g dry wt. • Further evaluation needed if 70- 250μg/g ,if active liver d/s or symptoms of WD
  • 44. LIVER BIOPSY • Mild steatosis- earliest • Auto immune hepatitis histologic findings • Cirrhotic changes-macronodular • marked hepatocellular degeneration & parenchymal collapse • Cu staining is variable- poor predictive value
  • 45. NEURO-IMAGING  Brain CT abnormalities: • 73% with ventricular dilation, 63% cortical atrophy, 55% brainstem atrophy, 45% hypodense areas in basal ganglia, and 10% posterior fossa atrophy. • MR imaging- evaluate neurologic WD & prior to treatment • MRI- T2 hyperintensity in basal ganglia,thalami
  • 46. GENETIC STUDIES • Molecular genetic testing has been available in recent years and is most helpful if the diagnosis remains in doubt • DNA mutation analysis can be performed for a defined ATP7B mutation, • common mutations in the appropriate ethnic population • haplotype (microsatellite) marker analysis if a first-degree relative has Wilson’s disease. • Prenatal diagnosis ???
  • 47.  Tests that appear to be of no value in establishing the diagnosis of Wilson’s disease • computed tomography (CT) scanning & • MRI of the liver,  because liver copper content cannot currently be detected or quantitated by these modalities
  • 48. AN ASYMPTOMATIC PATIENT IN WHOM A K-F RING IS FOUND ON ROUTINE OPHTHALMOLOGIC EXAMINATION ① a serum ceruloplasmin level should be performed. ② If it is low or there is high suspicion and it is normal, ③ a 24-hour urine copper excretion should be performed and consideration given to a liver biopsy. ④ Elevated urine copper excretion, a low ceruloplasmin, and a K-F ring establish the diagnosis. ⑤ However, if the liver or spleen is enlarged or liver blood tests are abnormal, a liver biopsy should be performed.
  • 49. ASYMPTOMATIC SIBLINGS OF WILSON’S DISEASE PATIENTS ① screened for the disease after age 3 or 4 years unless hepatomegaly or abnormal aminotransferase levels are found earlier. ② A thorough history and physical examination, slit-lamp examination, and laboratory analysis should be performed ③ If all tests are normal, it is very unlikely that the relative has Wilson’s disease ④ However, if any of those tests are abnormal, a liver biopsy should be performed for histology, electron microscopy, and quantitative copper analysis.
  • 50. ⑤ An alternative, less invasive approach is to evaluate the known patient, the sibling, and the parents for DNA haplotype (microsatellite markers) to determine if the sibling in question has inherited the Wilson’s disease gene. ⑥ Haplotype analysis is informative in over 90–95% of cases ⑦ Another approach is to genotype the affected relative and if ATP7B mutations are identified, to test the sibling in question for these mutations. ⑧ Finding two mutations or informative microsatellite markers will establish the diagnosis of Wilson’s disease and preclude the need for liver biopsy unless there are signs or symp- toms of chronic liver disease
  • 52. • Anti –copper drugs- -D-Pencillamine - Zinc - Trientene - Tetrathiomolybdate(TM) • Diet • Drinking water • Concomitant hepatic,neurological management • Liver transplantation
  • 53. D-PENICILLAMINE • a sulfhydryl- containing metabolite of penicillin • The actual mechanism on how this drug works is not known • “decoppering effect,” • “detoxification effect” • It is recommended to begin the penicillamine therapy with one fourth to half of the desired dose and increase the dose slowly over 1–2 weeks.
  • 54. • The dosage for older children and adults is 1 g of penicillamine orally per day in four divided doses given ideally at least 30 minutes before or 2 or more hours after meals. • If an overtly ill patient fails to show clinical improvement, the dosage can be increased to 1.5–2.0 g/d. • In young children, a dosage of 20 mg/kg/d rounded to the nearest multiple of 250 mg is given ideally in three divided doses • After stabilization, the dose may be divided into two or three daily doses not to be given with meals • D-penicillamine may have an antipyridoxine effect, thus all treated patients should also receive 25–50 mg of pyridoxine daily
  • 55. • During the first month of penicillamine therapy, the patient should be monitored weekly for fever or rash. • A complete blood count and platelet count, urinalysis, and renal and liver blood tests should be obtained every 1–2 weeks • If the patient responds appropriately with resolution of symptoms and normalization of liver blood tests, monitoring is performed every 1–3 months for the first year and every 6–12 months thereafter. • An annual 24-hour urinary copper excretion is helpful in mon- itoring chronic penicillamine therapy
  • 56. • In 10–50% of patients, neurologic symptoms worsened shortly after penicillamine therapy was started • Continued or altered penicillamine therapy generally resulted in reversal of this worsening although irreversible neurologic abnormalities have been reported • Thus, it is recommended that the penicillamine dosage be reduced to 250 mg/d if neurologic symptoms worsen and gradually increased every 4–7 days by 250 mg/d until urinary copper excretion exceeds 2000 μg/d
  • 57. TRIETHYLENE TETRAMINE DIHYDROCHLORIDE (TRIENTINE) • It does not contain sulfhydryl groups; rather it chelates copper by forming a stable complex with copper through its four nitrogen atoms in a planar ring. • better safety profile. • The initial dosage for adolescents and adults is 750–1500 mg daily in two to three divided doses before meals. • Maintenance therapy is typically 750 or 1000 mg/d. • In children, the dose generally used is 20 mg/kg/d rounded off to the nearest 250 mg. • The toxicity includes bone marrow suppression (a sideroblastic anemia), nephrotoxicity, and skin and mucosal lesions . • Female patients may become iron deficient and require iron supplementation
  • 58. AMMONIUM TETRATHIOMOLYBDATE • an alternative approach to the treatment of Wilson’s disease is based on whether the patient presents with neurologic or hepatic symptoms • Because up to 50% of patients in an earlier series who had neurologic disease showed worsening of their symptoms with penicillamine therapy, ammonium tetrathiomolybdate, for initial therapy in neurologically affected patients • it is absorbed and complexes with copper and albumin in blood, preventing cellular uptake and resulting in decreased intracellular copper stores • After 8 weeks, the drug was stopped and patients were maintained on oral zinc acetate, 50 mg three times a day
  • 59. - inhibit CU absorption - bind with copper (chelator) - used in neurological WD - S/E- anemia,neutropenia, hepatotoxicity - 120 mg/d ie. 20mg x 3 with meal 60mg bed time - 8 weeks therapy - weekly neurological examination
  • 60. ZINC THERAPY • Zinc has been proposed as maintenance or adjunctive therapy for Wilson’s disease. • Zinc inhibits intestinal absorption of copper • The dosage of zinc acetate, given between meals, that currently is advocated is 50 mg of elemental zinc three times daily or zinc sulfate, 150– 220 mg three times daily • Common side effects include headache and gastrointestinal upset, which are perhaps less common with zinc acetate. • Because of its slower onset of action, zinc therapy is generally not used as initial therapy for symptomatic patients. • Zinc therapy may play a role in presymptomatic patients or siblings • It should also be stressed that patients have deteriorated and developed fulmi- nant liver failure after the discontinuation of zinc therapy.
  • 61. ANTIOXIDANT THERAPY • Vitamin E, 400–1200 IU/d, may be given orally in divided doses with meals safely. • Because high-dose vitamin E may interfere with vitamin K– dependent clotting factor synthesis, the prothrombin time should be monitored and vitamin K supplementation used if necessary.
  • 62. LIVER TRANSPLANTATION • acute fulminant hepatic failure, • those with fulminant hepatic failure after inadvisably discontinuing copper chelation therapy • decompensated cirrhosis unresponsive to medical therapy • To better determine the criteria for referral for liver transplantation, Nazer et al. developed a prognostic index based on grading from 1–4 points the serum bilirubin concentration, serum AST, and prolongation of prothrombin time
  • 63. NAZER PROGNOSTIC INDEX Lab measureme nt normal value Score 0 Score 1 Score 2 Score 3 Score 4 Serum bilirubin 0.2-1.2 <5.8 5.8-8.8 8.9-11.7 11.8-17.5 >17.5 SGOT 10-35 <100 100-150 151-200 201-300 >300 PT prolongation diff. 12-14s <4s 4-8s 9-12 13-20 >20
  • 64. NAZER INDEX • Mild hepatic failure- score <6 survived with medical therapy • Moderate hepatic failure- 7-9 • Severe hepatic Failure - >9 fatal courses or required transplantation • The authors developed a new index based on serum bilirubin, INR, AST, albumin, and WBC at presentation. • A score greater than 11 of a possible 20 was predictive for death, with a 93% sensitivity, 98% specificity, and 88% positive predictive value
  • 65. SPECIAL CIRCUMSTANCES  PREGNANCY • During pregnancy, it is advisable to continue penicillamine therapy at a dosage of 750–1000 mg/d • Several patients who have discontinued therapy for longer periods during pregnancy have had episodes of acute hemolysis or worsening of liver disease including fulminant hepatic failure. • All children fathered by patients with Wilson’s disease have been normal • Although infants may be at a small risk for a connective tissue or skin abnormality during penicillamine therapy, the risk to mother and infant of discontinuing copper chelation therapy appears to be greater. • If cesarean section is anticipated, some authorities recommend reducing the dose of penicillamine to 250 mg/d 6 weeks before delivery to reduce the risk for impaired wound healing
  • 66.  SURGERY • Penicillamine has inhibitory effects on collagen cross- linking • Therefore, to prevent interference with wound healing, it is recommended that when patients with Wilson’s disease undergo surgery, the dose of penicillamine be reduced, but not stopped, for 10– 14 days postoperatively
  • 67. DIET • Avoid liver ,shell fishes,nuts,chocolate,mushroom • After 6-12 months Rx, one meal + shell fish/ wk • If enteral feeding,Cu <1.5 mg/d • Drinking water - < 0.1 ppm Cu
  • 68. ANTI COPPPER DRUGS Drugs Mode of action Neurological deterioration S/E Dosage monitoring D-pencillamine Chelator induces cupuria 1 20-40 % in initial phase BM suppression,ne phrotic syndrome, Hepatotoxicity,f ever, 250- 500mg/d,incre mental 250mg4-7d Max.1-1.5g/d ( 2-4 doses) Maint-750mg- 1g Pyridoxine- 25mg/d 24hr.U Cu-200- 500μg Free Cu- 10-15μg/dl 1,3,6,12,18, 24 months Then annually
  • 69. DRUGS MODE OF ACTION SIDE EFEECTS DOSAGE MONITOR Trientine Chelator induces cupuria Gastritis,aplastic anemia rare, Sideroblastic anemia 750-1500mg/d (2-3 doses) 20mg/kg/d(child Maint- 750-1000mg 24hr U.Cu & Non-ceruloplas Bound copper 1,3,6,12,18,24 months-annually Zinc Metallothione inducer, Inhibits Cu absoption Gastritis,pancreatitis ,Zn accumulation 150mg/d in 3 divided doses 75mg/d (child, <50 kg) 24hr .U.Cu- 50-125μg/d & 24h.U.Zn > 2mg/d 3,6 months,6 month 2yr,then yearly
  • 70. SUMMARY • WD- is an medical enigma with wide spectrum • Proper clinical examinations • Integrated diagnostic approach • Treatment for various clinical profiles • Zinc as a new paradigm shift in Rx • Hepatic transplantation • Monitoring., and prognosis • Lifelong Rx and normal expectancy • Fatal if not treated.